profit from every $100 of sales.
$0$100
Mainz Biomed
$0.62-9.53% today
-84.7% in 1 year
1-year low $0.621-year high $5.40
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Mainz Biomed sold, what it kept, and what it did with the cash.
Sales went from $529,877 in 2022 to $537,080 in 2025, with -$16.2 million of profit last year.
SalesProfit
Mainz Biomed vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Mainz Biomed | No profit yet | ||
 Illumina | 37.9× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Mainz Biomed's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 1 | 1 | 1 | |
| 0 | 1 | 1 | 0 | |
| -26 | -27 | -18 | -13 | |
| -26 | -25 | -20 | -15 | |
| -26 | -26 | -22 | -16 | |
| -74.55 | -64.76 | -21.91 | -2.70 | |
| 34.4% | 56.9% | 64.3% | 72.6% | |
| -4,990.6% | -2,975.5% | -2,063.8% | -2,414.0% | |
| -4,979.9% | -2,936.5% | -2,416.0% | -3,018.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 20 | 15 | 14 | 5 |
| Cash | 17 | 7 | 6 | 1 |
| Total debt | 3 | 7 | 4 | 3 |
| Total liabilities | 6 | 12 | 8 | 5 |
| 14 | 3 | 6 | 1 | |
| 0 | 0 | 1 | 6 | |
| -119.0% | -190.5% | -171.7% | -389.4% | |
| -187.2% | -809.3% | -360.1% | -2,526.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -15 | -22 | -17 | -11 | |
| 1 | 2 | 0 | 1 | |
| -15 | -24 | -18 | -12 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 10 | 4 | 1 | 3 |
Valuation
- –
- –
- –
- 6.5×
- 101.4×
- –
- –
- -22.1%
- -29.8%
- 0.0%
Profitability
- 72.6%
- -2,414.0%
- -3,018.3%
- -2,621.4%
- -165.6%
- -253.3%
- -244.2%
- -109.1%
- -170.2%
- 1,055.3%
Growth
- +0.5%
- –
- +30.6%
- –
- +140.2%
Financial health
- –
- 0.03
- 1.6%
- -39.1×
- 2.11
- 2.11
- 0.04
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 866
Bottom 4%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.21 | -38.80 | +99.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
33No pass
Philip Fisher
46No pass
Peter Lynch
41No pass
Joel Greenblatt
0No pass
Charlie Munger
55No pass
Terry Smith
46No pass
Questions about Mainz Biomed
Is Mainz Biomed a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Mainz Biomed AI analysis
What does Mainz Biomed do?
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is in Medical - Diagnostics & Research.
Does Mainz Biomed pay a dividend?
No. Mainz Biomed does not pay a dividend at the moment.
Is Mainz Biomed stock halal?
Yes. Mainz Biomed passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
How has Mainz Biomed stock done over the past year?
Down 84.7% over the past twelve months, to $0.62. It traded between $0.62 and $5.40 and is 88.4% below its high.
Who are Mainz Biomed's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Mainz Biomed's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.